Estimated average lifelong healthcare costs (euros) and effectiveness
| Base case (i.e. current care) | No delay | Difference | |
| Screening programme costs | - | 4125 | - |
| Hospital costs | 21 493 | 27 472 | 5979 |
| Medication costs (weighted per treatment group) | |||
| PEA (60%) | 40 297 | 55 094 | 14 797 |
| BPA (15%) | 27 636 | 37 619 | 9983 |
| PAH-targeted therapy (15%) | 27 679 | 37 449 | 9770 |
| No treatment (5%) | - | - | - |
| Total lifelong costs | 117 105 | 161 759 | 44 654 |
| Life expectancy years | 14.3 | 17.3 | 3.01 |
| QALYs years | 8.42 | 10.45 | 2.04 |
| Incremental cost-effectiveness ratio | 14 853 per life-year gained | ||
| Incremental cost–utility ratio | 21 910 per QALY gained | ||
PEA: pulmonary endarterectomy; BPA: balloon pulmonary angioplasty; PH: pulmonary hypertension; QALY: quality-adjusted life-year.